Makenzie Gordon Mabe, PA-C

Makenzie Mabe practices at Watson Clinic in Lakeland, Florida.

Makenzie Mabe's NPI, 1891392502, was assigned on October 6, 2020. Makenzie Mabe holds Florida license PA9113862.

Makenzie Mabe's primary practice is Watson Clinic, at 1430 Lakeland Hills Blvd, Lakeland, FL 33805 in Polk County. The practice phone is (863) 680-7700.

Makenzie Mabe's primary practice is Watson Clinic in Lakeland, Florida. Makenzie Mabe is also affiliated with Lakeland Regional Health Medical Center. The medical group on file is Watson Clinic. Dmand AI also links Makenzie Mabe to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Makenzie Mabe practices, 2 sites in all. Vendor and product names are available with a free account.

Physician assistant is Makenzie Mabe's primary specialty in the NPI Registry, under taxonomy code 363A00000X. Makenzie Mabe is licensed in Florida.

Dmand AI lists asthma, chronic indigestion, chronic kidney disease, chronic obstructive pulmonary disease (COPD), joint pain, muscle pain, fibromyalgia, and limb pain, sleep apnea and tobacco use among the conditions Makenzie Mabe treats.

CMS data shows 731 Medicare services from Makenzie Mabe across 3 procedure codes in 2024, for 419 Medicare patients. Medicare paid $50,635 for them. Every service was in an office.

CMS counts 419 Medicare patients who saw Makenzie Mabe in 2024. The largest group is 75 to 84, with 179 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 4% are also on Medicaid. Their average risk score is 1.85, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Makenzie Mabe's median patient age at 75, with 51% women.

In 2024, Makenzie Mabe wrote 2,229 Medicare Part D claims for 561 patients. 77% of them were for generic drugs. CMS names the drug for 2,094 of them, across 30 drugs with 11 or more claims each, at $442,181 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 87 out of 100 for Makenzie Mabe for performance year 2024, reported through an alternative payment model (APM). Makenzie Mabe accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 43 general payments to Makenzie Mabe from 11 drug and device companies from 2024 to 2025. Food and beverage make up the largest share, 100% of the total. Boston Scientific Corporation paid the most, $324.